ديجيتال فابلت

الوسم: skin cancer

  • Kerem Bürsin Gets Star Honor & Skin Cancer Screening in Azerbaijan

    Kerem Bürsin Gets Star Honor & Skin Cancer Screening in Azerbaijan

    Kerim Bürsin is making headlines in Turkey for two very distinct reasons—raising awareness about skin cancer while also receiving a star’s welcome in Azerbaijan, where he was honored with a spot on the Sea Breeze Walk of Fame.

    He first gained praise after participating in Euromelanoma 2026 Skin Cancer Awareness Week, joining one of Turkey’s leading public health initiatives aimed at encouraging early detection and routine skin checks.

    As part of this nationwide effort, Bürsin met with dermatologist Prof. Dr. Nazan Yılmaz, who conducted a thorough preventive skin cancer screening and discussed the importance of shielding the skin from harmful ultraviolet rays. During the visit, the actor shared that he considers himself to be at a higher risk due to his fair skin. He highlighted this as a reason for his regular dermatological exams and urged others to prioritize preventive care without delay.

    Bürsin emphasized that early detection makes skin cancer highly treatable and noted that many people wrongly wait until symptoms show before seeking help.

    Following his exam, Prof. Dr. Yılmaz confirmed that no concerning or abnormal results were found, reinforcing the message that routine health screenings are valuable even when feeling perfectly healthy.

    The event also aimed to dispel common myths about sun protection. During a “True or False” quiz, Bürsin discussed misconceptions such as whether sunlight through windows can damage skin, if sunscreen should only be applied once per day, if SPF 50 offers twice the protection of SPF 30, whether darker skin tones eliminate skin cancer risks, and if all skin cancers are hereditary.

    Medical professionals used this opportunity to remind the public that anyone, regardless of skin type, can develop skin cancer. They advised using sunscreen, avoiding excessive sun exposure, and having suspicious moles or skin changes evaluated by a dermatologist. Prof. Dr. Yılmaz expressed gratitude to Bürsin for supporting the Euromelanoma campaign, noting that when well-known figures participate, it significantly helps spread vital health messages to a broader audience.

    Just days later, Bürsin was again in the spotlight—this time in Baku, Azerbaijan. He received a warm welcome from fans during a special ceremony at Sea Breeze, one of the country’s premier lifestyle and entertainment destinations.

    He was celebrated with his own star on the Sea Breeze Walk of Fame, joining an international list of stars such as Ricky Martin and Will Smith. The event drew large crowds, many of whom waited hours to see the Turkish actor. Videos shared widely on social media showed Bürsin greeting supporters warmly, taking photos, signing autographs, and engaging with fans throughout the event. His approachable nature and openness to interaction became one of the most memorable aspects of the ceremony.

    Following the Walk of Fame event, Bürsin attended the International Boxing Association (IBA) gathering as a special guest. This high-profile occasion drew leaders in sports, entertainment, and business from around the world. Despite the presence of international boxing champions, Turkish media reported that Bürsin remained one of the evening’s biggest attractions, with attendees gathering around him throughout the event.

    These consecutive appearances highlight two facets of Bürsin’s expanding public profile. Back home, he continues to champion health awareness and encourages regular skin screenings, while internationally, his recognition in Azerbaijan underscores his continued global popularity gained through his acting career.

  • New Cream Boosts Immunity to Combat Skin Cancer

    New Cream Boosts Immunity to Combat Skin Cancer

    Scientists have created a groundbreaking skin cream that may enhance the body’s ability to combat a common type of skin cancer by activating its own immune defenses. Early findings published in the Journal of Clinical Investigation indicate that this cream could slow tumor growth and potentially prevent some skin cancers from progressing into more serious conditions.

    Developed by researchers at the Perelman School of Medicine at the University of Pennsylvania, the cream successfully stimulated the immune system within the skin in laboratory tests using preclinical models. It helped suppress the growth of tumors associated with cutaneous squamous cell carcinoma, often abbreviated as cSCC.

    With approximately one million new cases diagnosed annually in the United States alone, cutaneous squamous cell carcinoma is one of the world’s most prevalent cancers. Most instances are manageable if detected early and surgically removed. However, roughly five percent of these tumors can metastasize, spreading to other parts of the body. When that occurs, the disease becomes significantly more dangerous and leads to thousands of deaths each year.

    The incidence of this skin cancer is climbing, partly because people are living longer and partly due to increased sun exposure without adequate protection. Ultraviolet rays can damage the DNA in skin cells over time, raising the risk of cancer development.

    Current treatments primarily involve surgical removal, which, although often effective, can be uncomfortable and leave scars. For patients with numerous precancerous spots—especially older adults or those with weakened immune systems—repeated surgeries can be taxing and impractical.

    Existing therapies for widespread skin lesions are limited. Some systemic cancer drugs are not specifically targeted to skin cancer cells, and others can cause significant pain or adverse side effects. This has prompted researchers to look for simpler, more precise options.

    The innovative cream operates by targeting an enzyme called LSD1. Enzymes are proteins that facilitate chemical reactions within the body. Typically, LSD1 acts as a brake on immune signaling pathways in skin cells, helping to regulate immune responses. By inhibiting LSD1, the cream lifts this brake, allowing skin cells to send out signals that summon immune cells to the area. These immune cells can then identify and destroy tumor cells.

    Dr. Brian C. Capell, a dermatologist and lead researcher at the University of Pennsylvania, emphasized that this approach is promising because it leverages the body’s natural immune defenses instead of using aggressive drugs to attack the cancer directly.

    Further cellular studies revealed that a specific group of immune cells, called CD4-positive T cells, are essential in the process. When these cells were removed in experiments, the cream lost its ability to slow tumor growth, indicating that its effectiveness relies on communication between skin cells and the immune system.

    Researchers also observed that blocking a pathway called retinoic acid signaling reversed many of the effects caused by the cream, confirming this pathway’s role in immune activation.

    While the cream is still in the experimental stage and not yet available to patients, the findings are encouraging. Ongoing efforts aim to optimize its safety and effectiveness. In the next one to two years, scientists plan to initiate early clinical trials—known as Phase I studies—to test the treatment in humans for the first time.

    If subsequent research proves the cream to be safe and effective, it could provide a new method for treating both cancerous and precancerous skin conditions. Applied directly to affected areas, it could reduce the reliance on surgeries and help stop some lesions from developing into invasive cancers.

    Preventing the progression of skin cancer could significantly impact public health. An estimated 58 million Americans are living with precancerous skin conditions or early-stage squamous cell carcinoma. A treatment capable of halting these lesions could help many avoid more severe disease.

    Scientists are also exploring the potential of LSD1 inhibitors in other forms, such as oral pills or injections. These treatments could enhance existing immunotherapies that are currently used against advanced skin cancers but only benefit a subset of patients. Combining such strategies might lead to more effective and personalized skin cancer therapies.

    This research marks an important step toward harnessing the immune system to combat skin cancer in innovative ways, offering hope for more targeted and less invasive treatment options in the future.

    For additional insights on skin health, explore studies on how eating fish may increase skin cancer risk or Vitamin B3’s potential in preventing skin cancers. Further research covers topics like the link between vegetable oils and cancer spread, as well as how Vitamin D might aid in skin inflammation treatment.

  • New Study Suggests Vitamin B3 Supplement Could Help Prevent Skin Cancer

    New Study Suggests Vitamin B3 Supplement Could Help Prevent Skin Cancer

    Skin cancer ranks as the most prevalent type of cancer in many countries, particularly in regions with intense sunlight like the U.S. and Australia. Medical professionals have long advised people to safeguard their skin by using sunscreen, avoiding excessive sun exposure, and performing regular skin checks.

    Recently, researchers have started examining whether specific vitamins could help lower the risk of developing new skin cancers. One vitamin of interest is nicotinamide, a form of vitamin B3. This vitamin is related to niacin, another B3 variant that helps produce energy and repair cells. Unlike niacin, nicotinamide doesn’t cause skin flushing or redness. Scientists are interested in nicotinamide because it appears to enhance the body’s ability to fix DNA damage caused by ultraviolet light from the sun.

    When UV rays damage DNA inside skin cells, those cells may sometimes turn cancerous. Improving the body’s capacity to repair this damage could potentially decrease cancer development. The idea that nicotinamide might prevent skin cancer first gained traction in 2015 after a clinical trial involving 386 individuals with a history of skin cancer. Participants in this study took nicotinamide supplements regularly, and results showed they developed fewer new skin cancers compared to those who didn’t take the supplement. As a result, many dermatologists began recommending nicotinamide to their patients with a prior skin cancer history.

    However, that initial study involved a relatively small population. To verify whether the protective benefits would hold in a larger group, researchers sought a system that could accurately track nicotinamide use. They found such an opportunity within the U.S. Department of Veterans Affairs (VA) health system, where medication use is well-documented in medical records.

    In this large database, scientists analyzed data from over 33,800 veterans who had received nicotinamide treatment—typically at a dose of 500 milligrams twice daily for more than a month. They tracked whether these individuals later developed common nonmelanoma skin cancers, such as basal cell carcinoma and cutaneous squamous cell carcinoma, which are frequently linked to long-term sun exposure.

    Among the study participants, approximately 12,300 had taken nicotinamide, while 21,500 had not. Comparing the two groups, researchers found that those who used nicotinamide had a 14% lower risk of developing new skin cancers. The reduction was even more significant in patients who started taking the supplement after their first skin cancer diagnosis, with their risk decreasing by about 54%. This suggests that initiating nicotinamide soon after an initial diagnosis might produce the greatest benefit. Conversely, the protective effect was less pronounced in patients who had a history of multiple skin cancers before beginning supplementation.

    The study also indicated that nicotinamide was particularly effective in reducing the risk of squamous cell carcinoma, a common and sometimes aggressive skin cancer that can spread if not detected early. Basal cell carcinoma, though more common, rarely spreads.

    Led by Dr. Lee Wheless from Vanderbilt University Medical Center and the VA Tennessee Valley Healthcare System, the research underscores the potential of nicotinamide as a preventative measure. Currently, no clear guidelines exist on the best timing to begin taking the supplement, with many doctors recommending it only after multiple skin cancers have appeared. These new findings suggest that earlier intervention could be more beneficial in high-risk individuals.

    While the data is promising, some limitations remain. Since many people buy nicotinamide over the counter, without a prescription, its usage isn’t always recorded—making it hard to study long-term effects comprehensively. Using the VA health system’s detailed records provided an invaluable opportunity to analyze outcomes across thousands of patients.

    Overall, the findings support the idea that nicotinamide could be a useful addition to skin cancer prevention strategies for those at higher risk. Because the study involved a large number of participants, it offers a strong piece of evidence compared to earlier smaller trials. Nonetheless, since it’s an observational study based on medical records, it shows associations rather than establishing complete causality.

    Nicotinamide is affordable, widely accessible, and generally deemed safe at recommended doses. If future research confirms these benefits, it might become a simple and inexpensive tool to help prevent some skin cancers, especially in those with a history of the disease. Still, experts caution that nicotinamide should not replace traditional protection methods like sunblock, protective clothing, and regular skin exams. Instead, it may serve as an additional safeguard for high-risk populations.

    For those interested in cancer prevention, recent studies suggest that common anti-inflammatory drugs could help kill cancer cells, and statins might starve cancer cells of nutrients. Additionally, research has pointed to the potential role of certain Indian fruits in slowing down cancer growth.